SERA PROGNOSTICS, INC.

Listed Company

SERACIK 0001534969NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthServices-Medical LaboratoriesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$81.0K

Net Income

$-31.93M

Total Assets

$101.93M

Equity

$75.41M

Shares Out

29.29M

Op. Cash Flow

$-25.62M

Business

SERA PROGNOSTICS, INC. is a women’s health company that discovers, develops and commercializes blood-based biomarker tests and predictive analytic products to improve maternal and neonatal health. Its main offerings include the PreTRM test for predicting spontaneous preterm birth and a pipeline of additional biomarker tests, a molecular time-to-birth product, and predictive analytics tools. The company operates through clinical laboratory testing, proteomics and bioinformatics discovery and validation, and commercialization efforts. It distributes tests via clinician-ordered channels, payer collaborations, institutional partners and direct-to-consumer options across the United States and select international collaborations.

Summary from filing dated 2025-03-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	81,000	77,000	306,000	268,000	82,000
Cost of revenue	164,000	82,000	210,000	—	—
Research and development	13	15	15	14	11
Selling and marketing	7	6	8	15	10
General and administrative	17	16	16	17	14
Total operating expenses	37	37	40	46	35
Loss from operations	−37	−37	−40	−46	−35
Interest expense	−9,000	−28,000	−55,000	—	—
Other income, net	5	4	4	2	1
Net loss	−32	−33	−36	−44	−35
Net loss per share, basic	−0.67	−0.99	−1.16	−1.43	−2.33
Net loss per share, diluted	−0.67	−0.99	−1.16	−1.43	−2.33
Weighted-average shares outstanding, basic	48	33	31	31	15
Weighted-average shares outstanding, diluted	48	33	31	31	15
Unrealized gain on available-for-sale debt securities, net of tax	202,000	75,000	966,000	−798,000	−183,000
Total other comprehensive income	202,000	75,000	966,000	−798,000	−183,000
Comprehensive loss	−32	−33	−35	−45	−35

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	4	4	4	30	59
Marketable securities	35	42	45	53	46
Accounts receivable	12,000	34,000	160,000	113,000	27,000
Prepaid expenses and other current assets	2	1	795,000	1	2
Total current assets	41	48	61	90	110
Property and equipment, net	1	1	2	3	2
Long-term marketable securities	57	22	31	21	35
Intangible assets, net	910,000	1	0	—	—
Other assets	3	737,000	1	2	157,000
Total assets	102	73	95	116	147
Accounts payable	862,000	2	1	2	1
Accrued and other current liabilities	3	2	3	4	4
Finance lease obligation, current portion	2,000	194,000	440,000	464,000	74,000
Deferred revenue	20	20	20	9	3
Total current liabilities	24	25	24	16	8
Finance lease obligation, net of current portion	0	2,000	196,000	626,000	54,000
Operating lease obligation, net of current portion	2	0	644,000	1	0
Total liabilities	27	25	25	17	8
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock, $0.0001 par value; 150,000,000 Class A shares authorized; 37,976,764 and 33,206,909 Class A shares issued and outstanding as of December 31, 2025 and 2024, respectively; 1,500,000 Class B shares authorized; 967,759 Class B shares issued and outstanding as of December 31, 2025 and 2024.	4,000	3,000	3,000	3,000	3,000
Additional paid-in capital	387	328	317	311	305
Accumulated other comprehensive income	262,000	60,000	−15,000	−981,000	−183,000
Accumulated deficit	−312	−280	−247	−211	−166
Total stockholders' equity	75	48	70	99	139
Total liabilities and stockholders' equity	102	73	95	116	147

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	940,000	833,000	900,000	800,000	700,000
Stock-based compensation	5	7	5	5	3
Non-cash lease expense	492,000	567,000	526,000	462,000	0
Non-cash investment income, net	314,000	−910,000	−1	−239,000	—
Other	−5,000	−69,000	18,000	−22,000	90,000
Accounts receivable	22,000	126,000	−47,000	−86,000	−25,000
Other receivables	19,000	11	−5	−3	−3
Prepaid expenses and other assets	−352,000	−10,000	465,000	718,000	−2
Accounts payable	−1	455,000	−442,000	352,000	603,000
Accrued and other current liabilities	682,000	−575,000	−2	−514,000	1
Deferred revenue	92,000	−12,000	11	6	3
Net cash used in operating activities	−26	−14	−27	−35	−32
Purchases of marketable securities	−88	−36	−54	−48	−82
Proceeds from maturities and sales of marketable securities	60	49	54	54	800,000
Purchases of property and equipment	−726,000	−56,000	−128,000	−791,000	−1
Purchase of intangible assets	0	−1	0	—	—
Net cash (used in) provided by investing activities	−29	12	438,000	6	−83
Proceeds from public offering of common stock, net of issuance costs	54	—	—	—	—
Proceeds from exercise of stock options	507,000	3	1	308,000	592,000
Proceeds from employee stock purchase plan	103,000	147,000	123,000	0	—
Finance lease principal payments	−194,000	−440,000	−466,000	−303,000	−70,000
Net cash provided by financing activities	54	3	752,000	5,000	160
Net (decrease) increase in cash and cash equivalents	−99,000	163,000	−26	−29	45
Cash paid for interest	9,000	28,000	55,000	48,000	1
Issuance of stock to settle accrued and other current liabilities	0	406,000	0	—	—
Purchases of property and equipment in accounts payable and accrued and other current liabilities	9,000	0	20,000	0	154,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro